Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo

Molecular Carcinogenesis

Volumn 53, Issue 9, 2014, Pages 722-735

  Chien, Wenwen ^a   Lee, Dhong Hyun ^b   Zheng, Yun ^b,c   Wuensche, Peer ^a   Alvarez, Rosie ^b   Wen, Ding Ling ^a   Aribi, Ahmed M ^b   Thean, Su Ming ^a   Doan, Ngan B ^d   Said, Jonathan W ^d   Koeffler, H Phillip ^a,b,e  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e National University Cancer Institute   (Singapore)

Author keywords

4EBP1; Hypoxia; Panobinostat; Thioredoxin

Indexed keywords

ADRENOMEDULLIN; AUTOPHAGY PROTEIN 5; BELINOSTAT; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DEATH RECEPTOR 5; EPIDERMAL GROWTH FACTOR; GEMCITABINE; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN 1; LIGHT CHAIN 3; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; OXYGEN; PANOBINOSTAT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; THIOREDOXIN; THIOREDOXIN INTERACTING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VORINOSTAT; HIF1A PROTEIN, HUMAN; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE; MTOR PROTEIN, HUMAN; SULFONAMIDE; TARGET OF RAPAMYCIN KINASE;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER GROWTH; CANCER INHIBITION; CELL KILLING; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG POTENTIATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIGHT CHAIN; MONOTHERAPY; MOUSE; MTT ASSAY; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPLENOMEGALY; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CELL CYCLE; DRUG EFFECTS; GENETICS; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; TUMOR CELL CULTURE;

MUS;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IN VITRO TECHNIQUES; INDOLES; MICE; NF-KAPPA B; PANCREATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SULFONAMIDES; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84906226036     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22024     Document Type: Article

References (47)

1. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011; 378:607-620.
2. Jenks S. AACR highlights: Promise for treating pancreatic cancer. J Natl Cancer Inst 2011; 103:766-767.
3. Colucci G, Labianca R, Di Costanzo F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: The GIP-1 study. J Clin Oncol 2010; 28:1645-1651.
4. Adachi Y, Yamamoto H, Ohashi H, et al. A candidate targeting molecule of insulin-like growth factor- I receptor for gastrointestinal cancers. World J Gastroenterol 2010; 16:5779-5789.
5. Kim LC, Song LX, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009; 6:587-595.
6. Janku F, Lee JJ, Tsimberidou AM, et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS ONE 2011; 6:e22769.
7. McCarthy N. Pancreatic cancer on your marks. Nat Rev Cancer 2009; 9:846.
8. Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467:1109-1113.
9. Dong XQ, Jiao L, Li YA, et al. Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. J Clin Oncol 2009; 27:1592-1599.
10. Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009; 15:3958-3969.
11. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000; 92:1210-1216.
12. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell 2003; 4:13-18.
13. Li Y, Kao GD, Garcia BA, et al. A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. Genes Dev 2006; 20:2566-2579.
14. Candido EPM, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured-cells. Cell 1978; 14:105-113.
15. Natoni F, Diolordi L, Santoni C, Montani MSG. Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways. Biochim Biophys Acta-Mol Cell Res 2005; 1745:318-329.
16. Kumagai T, Wakimoto N, Yin D, et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 2007; 121:656-665.
17. Carew JS, Medina EC, Esquivel JA, et al. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med 2010; 14:2448-2459.
18. Gahr S, Ocker M, Ganslmayer M, et al. The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells. Int J Oncol 2007; 31:567-576.
19. Lee DH, Thoennissen NH, Goff C, et al. Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma. Cancer Lett 2011; 306:161-170.
20. Kavanaugh SA, White LA, Kolesar JM. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. Am J Health-Syst Pharm 2010; 67:793-797.
21. Lassen U, Molife LR, Sorensen M, et al. A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. Br J Cancer 2010; 103:12-17.
22. Mackay HJ, Hirte H, Colgan T, et al. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer 2010; 46:1573-1579.
23. Gimsing P, Hansen M, Knudsen LM, et al. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol 2008; 81:170-176.
24. Wedel S, Hudak L, Seibel JM, et al. Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer. Prostate 2011; 71:722-735.
25. Lee KH, Choi EY, Kim MK, et al. Inhibition of histone deacetylase activity down-regulates urokinase plasminogen activator and matrix metalloproteinase-9 expression in gastric cancer. Mol Cell Biochem 2010; 343:163-171.
26. Shimura H, Furuya F, Aoyagi M, Ohta K, Endo T, Kobayashi T. A proteosome inhibitor synergizes with histone deacetylase inhibitor-induced cell death and redifferentiation of thyroid carcinoma cells. Endocr J 2010; 57:S463.
27. Huang XP, Gao LZ, Wang SL, Lee CK, Ordentlich P, Liu BL. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression. Cancer Res 2009; 69:8403-8411.
28. Park JH, Kim SH, Choi MC, et al. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem Biophys Res Commun 2008; 368:318-322.
29. Park MA, Zhang G, Martin AP, et al. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther 2008; 7:1648-1662.
30. Arnold NB, Arkus N, Gunn J, Korc M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 2007; 13:18-26.
31. Kauh J, Fan S, Xia M, et al. c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS ONE 2010; 5:e10376.
32. Duan JM, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C. Nuclear factor-kappa B p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2007; 6:37-50.
33. Bianco RB, Melisi D, Ciardiello F, Tortora G. Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer 2006; 42:290-294.
34. Kawamata N, Chen J, Koeffler HP. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood 2007; 110:2667-2673.
35. Nishioka C, Ikezoe T, Yang J, Takeuchi S, Koeffler HP, Yokoyama A. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. Leuk Res 2008; 32:1382-1392.
36. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011; 11:393-410.
37. Guillemin K, Krasnow MA. The hypoxic response: Huffing and HIFing. Cell 1997; 89:9-12.
38. Cannito S, Novo E, Compagnone A, et al. Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis 2008; 29:2267-2278.
39. Ouafik L, Sauze S, Boudouresque F, et al. Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo. Am J Pathol 2002; 160:1279-1292.
40. Martinez A, Vos M, Guedez L, et al. The effects of adrenomedullin overexpression in breast tumor cells. J Natl Cancer Inst 2002; 94:1226-1237.
41. Keleg S, Kayed H, Jiang XH, et al. Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion. Int J Cancer 2007; 121:21-32.
42. Sackett DL, Ozbun L, Zudaire E, et al. Intracellular proadrenomedullin-derived peptides decorate the microtubules and contribute to cytoskeleton function. Endocrinology 2008; 149:2888-2898.
43. Welsh SJ, Bellamy WT, Briehl MA, Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1 alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 2002; 62:5089-5095.
44. Wang XF, Zhang JS, Xu TW. Thioredoxin reductase inactivation as a pivotal mechanism of ifosfamide in cancer therapy. Eur J Pharmacol 2008; 579:66-73.
45. Butler LM, Zhou XB, Xu WS, et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 2002; 99:11700-11705.
46. Shamji AF, Nghiem P, Schreiber SL. Integration of growth factor and nutrient signaling: Implications for cancer biology. Mol Cell 2003; 12:271-280.
47. Tanida I, Ueno T, Kominami E. LC3 conjugation system in mammalian autophagy. Int J Biochem Cell Biol 2004; 36:2503-2518.